This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Results
The expected costs were $93,538 with active surveillance plus decolonisation, $107,971 with active surveillance alone, and $141,300 with no surveillance. Projected rates of MRSA infection avoided and infection-related deaths avoided were 96.07 and 99.57 with active surveillance plus decolonisation, 95.69 and 99.49 with active surveillance alone and 92.94 and 99.29 with no surveillance. Incremental analysis showed that active surveillance plus decolonisation was the dominant strategy as it was simultaneously more effective and less expensive than the other comparators. Active surveillance alone dominated no surveillance.
The base case results held in almost all scenarios. Exceptions were when assuming extremely low estimates for the direct benefit of decolonisation (active surveillance alone was the dominant strategy in this case) or very low risk of hospital-acquired MRSA infection in non-carriers or very low cost of hospital-acquired MRSA infection (in these cases no surveillance was the dominant strategy).
The probabilistic analysis showed that active surveillance plus decolonisation remained the dominant strategy in all simulations.
Authors' conclusions
The authors concluded that the model results strongly supported implementation of an active surveillance plus decolonisation protocol from the perspective of the hospital.
CRD commentary

Interventions:
The selection of comparators was appropriate and applicable to other health care settings and institutions. Active surveillance alone was the practice at Veterans Health Administration facilities at the time of the study.
Effectiveness/benefits:
Clinical inputs were retrieved by means of a review of the literature that should have identified key studies for each model parameter. However, the selected studies were not described and this hindered an objective assessment of the validity of the clinical sources. Some assumptions were required and were justified. Clinical parameters varied extensively in the sensitivity analyses. Both benefit measures were disease-specific and did not allow comparison with the benefits of other health care interventions.
Costs:
The cost categories were appropriate given the viewpoint of the hospital. Details of unit costs were presented for most items. Cost of MRSA infection was reported as a macro-category. Most economic data were based on published sources but the methodological features were not reported. The impact of variations in economic inputs was investigated extensively in sensitivity analyses, which also considered probability distributions for costs. Reflation exercises in other time periods would not be feasible as the price year was not clearly stated.
Analysis and results:
The study results were clearly presented. Use of an incremental analysis allowed the identification of the optimal (dominant) strategy. The authors provided a clear description of the decision models. Some shortcomings of the simulation (short time horizon and static nature of the model) were pointed out. A longer time horizon might have allowed analysis of potential recolonisation, which can have consequences for the cost-effectiveness issue of the active surveillance plus decolonisation strategy. The issue of uncertainty was investigated satisfactorily. Results of the sensitivity analyses were presented clearly and discussed. The authors stated that previous economic evaluations had
